Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 10/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HMGCR | P04035 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5515215 | 0.90 | TNF (0.41) | KDM4ETNFALDH1A1DPP4 | |
| SCHEMBL6000247 | 0.85 | KDM4E (0.36) | KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL6000006 | 0.84 | LMNA (0.48) | KDM4ETNFALDH1A1KMT2ANPC1 | |
| SCHEMBL5511478 | 0.83 | TNF (0.39) | KDM4ETNFALDH1A1 | |
| SCHEMBL5512764 | 0.83 | TNF (0.39) | KDM4ETNFALDH1A1 | |
| SCHEMBL5512849 | 0.81 | TNF (0.39) | KDM4ETNFALDH1A1DPP4 | |
| SCHEMBL5516130 | 0.77 | KDM4E (0.42) | KDM4EALDH1A1DPP4 | |
| SCHEMBL5512207 | 0.77 | MYC (0.42) | KDM4EALDH1A1DPP4 | |
| SCHEMBL5517826 | 0.76 | MAPT (0.45) | KDM4EALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL5524774 | 0.76 | KDM4E (0.43) | KDM4EALDH1A1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060074074-A1 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2006-04-06 | — | — | US | disclosed |
| EP-1026167-B1 | TRICYCLIC TRIAZOLOBENZAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND ANTIALLERGIC AGENTS | MEIJI SEIKA KAISHA (JP) | 2003-03-05 | — | — | EP | disclosed |
| EP-1026167-A1 | TRICYCLIC TRIAZOLOBENZAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND ANTIALLERGIC | MEIJI SEIKA KAISHA LTD. (JP) | 2000-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074074-A1 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | HRH4, CYP2D6, CYP2B6 | KDM4E 752/4885TNF 4043/4885ALDH1A1 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.